Complaint Counsel's Post Trial Brief - Federal Trade Commission

products in the treatment or cure of cancer, in inhbiting tuor formation, and in
preventing the destrctive effects of
radiation and chemotherapy. (CX 52 at 31).
Bio*Shark
the documents Respondents
submitted as substantiation indicates that there was no competent and reliable scientific
evidence that Bio*Shark inhbits tuor growth in humans or that it is effective in the
treatment of cancer in humans. (CX 52 at 13).
223. Dr. Miler's review of the peer-reviewed literatue and all of
224. Dr. Miler found that there were no adequate and well-controlled studies demonstrating
that Bio*Shark is antiangiogenic or is effective in the treatment of cancer, and even
supporting non-clinical studies of crude or parially-purfied shark carilage products
were extremely limted, paricularly with regard to mechansms of action,
pharacokietics, pharacodynamics, and dose response. (CX 52 at 17).
225. Dr. Miler obsered that Respondents' reliance on Dr. I. Wiliam Lane's book, "Sharks
Don't Get Cancer" was misplaced, as studies at Johns Hopkis University indicate that
sharks do indeed get cancer. (CX 52 at 16).
7 Herb Formula
the documents Respondents
submitted as substantiation indicates that there was no competent and reliable scientific
evidence that 7 Herb Formula inhbits tuor formation and is effective in the treatment
or cure of cancer in humans. (CX 52 at 18).
226. Dr. Miler's review of the peer-reviewed literatue and all of
227. Dr. Miler found neither non-clinical nor clincal studies supporting claims that 7 Herb
Formula or any of its individual ingredients are effective anticancer agents or inhbit
tuor formation. (CX 52 at 19).
228. Any relevant studies on the ingredients Burdock root, Cat's Claw, sheep sorrel, slipper
elm bark, tukish rhubarb root, Siberan giseng, and watercress were perormed either in
vitro or on anals, not on humans with cancer. (CX 52 at 19-22).
GDU
the documents Respondents
submitted as substantiation indicates that there was no competent and reliable scientific
evidence that GDU elimiates tuors and is effective in the treatment of cancer in
humans. (CX 52 at 22).
229. Dr. Miler's review of the peer-reviewed literatue and all of
230. Dr. Miler found no randomized, controlled clincal trals of any ofthe individual
components of GDU or of GDU itself in patients with cancer. (CX 52 at 27).
231. Dr. Miler, however, did note that curcumin (tuerc), one of GDU's ingredients, is
curently being evaluated in controlled clinical trals to detere its potential as a
chemoprotective and cancer preventive agent. (CX 52 at 22).
232. Anmal studies have suggested that curcumin may have activity as a cancer preventive
and therapeutic agent. (CX 52 at 23).
23